These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36539128)

  • 21. Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis.
    Hu XW; Qin SM; Li D; Hu LF; Liu CF
    Acta Neurol Scand; 2013 Aug; 128(2):73-82. PubMed ID: 23432663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
    Anamnart C; Kitjarak R
    J Clin Neurosci; 2021 Jun; 88():226-231. PubMed ID: 33992189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
    Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
    Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperhomocysteinemia in patients with Parkinson's disease and relationship to vitamin B level.
    Shin HW; Sohn YH
    J Mov Disord; 2009 May; 2(1):33-6. PubMed ID: 24868350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations.
    O'Suilleabhain PE; Sung V; Hernandez C; Lacritz L; Dewey RB; Bottiglieri T; Diaz-Arrastia R
    Arch Neurol; 2004 Jun; 61(6):865-8. PubMed ID: 15210523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients.
    Yuan RY; Sheu JJ; Yu JM; Hu CJ; Tseng IJ; Ho CS; Yeh CY; Hung YL; Chiang TR
    J Neurol Sci; 2009 Dec; 287(1-2):64-8. PubMed ID: 19786283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
    Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P
    Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated homocysteine levels in Parkinson's Disease: is there anything besides L-dopa treatment?
    Zoccolella S; dell'Aquila C; Specchio LM; Logroscino G; Lamberti P
    Curr Med Chem; 2010; 17(3):213-21. PubMed ID: 20214564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated levels of methylmalonate and homocysteine in Parkinson's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis.
    Levin J; Bötzel K; Giese A; Vogeser M; Lorenzl S
    Dement Geriatr Cogn Disord; 2010; 29(6):553-9. PubMed ID: 20606437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications.
    Hassin-Baer S; Cohen O; Vakil E; Sela BA; Nitsan Z; Schwartz R; Chapman J; Tanne D
    Clin Neuropharmacol; 2006; 29(6):305-11. PubMed ID: 17095893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias.
    Zoccolella S; Lamberti P; Iliceto G; Dell'Aquila C; Diroma C; Fraddosio A; Lamberti SV; Armenise E; Defazio G; de Mari M; Livrea P
    Clin Chem Lab Med; 2006; 44(7):863-6. PubMed ID: 16776634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical and clinical effects of Whey protein supplementation in Parkinson's disease: A pilot study.
    Tosukhowong P; Boonla C; Dissayabutra T; Kaewwilai L; Muensri S; Chotipanich C; Joutsa J; Rinne J; Bhidayasiri R
    J Neurol Sci; 2016 Aug; 367():162-70. PubMed ID: 27423583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease.
    Lee SH; Kim MJ; Kim BJ; Kim SR; Chun S; Ryu JS; Kim GS; Lee MC; Koh JM; Chung SJ
    Mov Disord; 2010 Feb; 25(3):332-40. PubMed ID: 19938151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients.
    Gorgone G; Currò M; Ferlazzo N; Parisi G; Parnetti L; Belcastro V; Tambasco N; Rossi A; Pisani F; Calabresi P; Ientile R; Caccamo D
    Neuromolecular Med; 2012 Mar; 14(1):84-90. PubMed ID: 22354693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia.
    Guo G; Xu S; Cao LD; Wu QY
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2409-12. PubMed ID: 27338068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contra-Directional Expression of Serum Homocysteine and Uric Acid as Important Biomarkers of Multiple System Atrophy Severity: A Cross-Sectional Study.
    Chen D; Wei X; Zou J; Wang R; Liu X; Xu X; Lu J; Wang Z; Tang B; Wang B; Jin K; Wang Q
    Front Cell Neurosci; 2015; 9():247. PubMed ID: 26217177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Homocysteine and its role in pathogenesis of Parkinson's disease and other neurodegenerative disorders].
    Szadejko K; Szabat K; Ludwichowska A; Sławek J
    Przegl Lek; 2013; 70(7):443-7. PubMed ID: 24167945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?
    Kocer B; Guven H; Comoglu SS
    Biomed Res Int; 2016; 2016():7563705. PubMed ID: 27493964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.
    dos Santos EF; Busanello EN; Miglioranza A; Zanatta A; Barchak AG; Vargas CR; Saute J; Rosa C; Carrion MJ; Camargo D; Dalbem A; da Costa JC; de Sousa Miguel SR; de Mello Rieder CR; Wajner M
    Metab Brain Dis; 2009 Jun; 24(2):257-69. PubMed ID: 19294496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum Homocysteine Level Predictive Capability for Severity of Restenosis Post Percutaneous Coronary Intervention.
    Guo J; Gao Y; Ahmed M; Dong P; Gao Y; Gong Z; Liu J; Mao Y; Yue Z; Zheng Q; Li J; Rong J; Zhou Y; An M; Gu L; Zhang J
    Front Pharmacol; 2022; 13():816059. PubMed ID: 35685647
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.